While it’s hard to overstate the success Novo Nordisk’s GLP-1 franchise has already achieved, the company’s latest deep dive ...

This week’s episode of “The Top Line,” is the final part of a three-part series diving into the latest advancements in cell ...

AstraZeneca's CEO wants to tap into China's innovation explosion. The company inked an oncology antibody deal with Harbour ...

Since scoring approval two years ago for its next-generation diabetes treatment Mounjaro (tirzepatide), Eli Lilly has been ...

Over the years, melanoma has become a popular testing ground for researchers to explore new immuno-oncology approaches. | ...

The Bavencio-Inlyta combo showed a favorable trend, reducing the risk of death by 14% compared with Pfizer’s Sutent as a ...

That’s according to a new survey and report from IQVIA, timed to come out alongside this year’s American Society of Clinical ...

Eli Lilly has in the past few months unveiled two back-to-back trial flops for Verzenio in prostate cancer. Now, we know ...

In the first personal injury case that has gone to trial over Zantac, GSK and Boehringer Ingelheim have emerged with an important victory as a Chicago jury has rejected the claim of Angela Valadez ...

After a report of leaking product, Pfizer’s Hospira unit is pulling five lots of sterile injectable medicines from ...

Apellis Pharmaceuticals is taking a slow and steady approach to advertising Syfovre, its treatment for geographic atrophy (GA ...

Over the last four years, with President Joe Biden milking a popular cause as an opponent of Big Pharma drug pricing, the ...